Acino Appoints Sunil Bhilotra as Managing Director and Interim CEO
Zurich, Switzerland – 28 October 2022 – Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced the appointment of Sunil Bhilotra as Managing Director and interim Chief Executive Officer (CEO). Steffen Saltofte has stepped down as CEO of Acino Group.
Sunil Bhilotra, Board member of Acino Group and Director of Portfolio Management, Healthcare, Pharma and Life Sciences at ADQ, has been appointed as Managing Director and interim CEO to ensure full business continuity for Acino as a leading provider of high-quality pharmaceuticals.
Acino is a leader in more than twenty therapeutic areas, including cardiovascular, gastroenterology, and pain relief, delivering high-quality pharmaceutical products in novel drug delivery forms to promote affordable healthcare in growth-leading markets. As a trusted partner to leading pharmaceutical companies worldwide, Acino also supplies bespoke solutions through contract manufacturing and out-licensing.
The Board of Directors and Executive management team wish to thank Steffen Saltofte for his commitment, vision and contribution to the growth of Acino as CEO over the past four years.
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Russia, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi-based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.
For more information, please contact:
Larisa Bernstein, Global Head of Communications